^
    myChoice® CDx Plus is the most comprehensive tumor test that determines HRD status in patients with ovarian cancer, fallopian tube and primary peritoneal cancer. This CE marked test helps to identify ovarian cancer patients with a Homologous Recombination Deficiency who might be considered for treatment with PARPi therapy.
    Cancer:
    Ovarian Cancer
    Gene:
    HRD (Homologous Recombination Deficiency)
    Method:
    Next-Generation Sequencing (NGS)